Most people with diabetic retinopathy do not have any symptoms or visual loss due to their retinopathy. However, without treatment, diabetic retinopathy can gradually become worse and lead to visual loss or even blindness. Diabetic retinopathy is the most common cause of blindness in working age adults in many western countries.
Slowing the development of diabetic retinopathy relies on good control of blood sugar and blood pressure. ACE inhibitors and ARBs are beneficial in hypertensive diabetics, but not appropriate for non-hypertensives. Injections with anti-VEGF drugs are being considered in some cases to retard the progression of diabetic retinopathy, but this is a very invasive form of preventive treatment.
Oculis OC410 candidate is being developed as a preventive treatment for diabetic retinopathy. The candidate is in the form of an eye drop and is financed through a Eurostars grant awarded to Oculis and collaborating researchers.